-+ 0.00%
-+ 0.00%
-+ 0.00%

Optimi Health wins Health Canada authorization for Phase 2 psilocybin trial in major depression

PUBT·09/10/2026 12:45:34
Listen to the news
Optimi Health wins Health Canada authorization for Phase 2 psilocybin trial in major depression
  • Health Canada cleared Optimi Health to proceed with a multisite Phase 2 trial of psilocybin-assisted therapy for major depressive disorder.
  • Trial start targeted for H1 2027. Enrollment up to 200 participants across Canada. Dosing expected to finish by end-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100845PRIMZONEFULLFEED9824250) on September 10, 2026, and is solely responsible for the information contained therein.